Completed PHASE3 INTERVENTIONAL NCT00201994

SALT-2 Trial Study of Ascending Levels of Tolvaptan in Hyponatremia

Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia, Study 2

Sponsor: Otsuka Pharmaceutical Co., Ltd.

Conditions Hyponatremia Inappropriate ADH Syndrome Water Intoxication Water-electrolyte Imbalance

Interventions Tolvaptan

Updated 5 times since 2017 Last updated: May 2, 2012 Started: Nov 30, 2003 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hyponatremia and Inappropriate ADH Syndrome, this trial is completed. The trial is conducted by Otsuka Pharmaceutical Co., Ltd. and has accumulated 5 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Development & Commercialization, Inc.

Data source: Otsuka Pharmaceutical Development & Commercialization, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gustav Carus, Germany